Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, announces it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). The strategic collaboration includes an exchange of Agenus’ state-of-the-art biologics CMC facilities in Emeryville, CA and Berkeley, CA for upfront consideration of $75M; Agenus to receive up to an additional $50M in contingent payments triggered by BOT/BAL production orders.
Read the full article: Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US //
Source: https://www.businesswire.com/news/home/20250603011983/en/Agenus-and-Zydus-Lifesciences-Enter-%24141M-Strategic-Collaboration-to-Advance-BOTBAL-Expand-Zydus-Biologics-Manufacturing-in-the-US